Solidifying a new corporate structure, IFM launches second unit focused on cGAS-STING
For Gary Glick and his crew at IFM, life after spinning out their oncology assets to Bristol-Myers Squibb has involved constant discussions about which targets — out of all the ideas on their drawing board — to go after in the adaptive immune system. Their next big question? When they should launch a new subsidiary to pursue the drugs, or how many of these units to form.
Those discussions led to IFM Tre, which got started last July with $31 million to tackle a troika of NLRP3 targets. With one of those programs on the cusp of entering the clinic, Glick is now ready announce their next venture: IFM Due (pronounced “du-way,” Italian for “two”), committed to the cGAS-STING pathway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
